Volume 29, Issue 3
DOI: 10.24205/03276716.2020.725
Therapeutic Effects of Hemoperfusion Combined with High Volume Hemofiltration on Acute Respiratory Distress Syndrome Short Title: Treatment of ARDS
Abstract
We aimed to analyze the impacts of hemoperfusion (HP) plus high-volume hemofiltration (HVHF) on acute respiratory distress syndrome (ARDS). Eighty ARDS patients were randomly distributed into a control group and an HP combined with HVHF group (n=40). Both groups received HVHF treatment. On this basis, HP HVHF group was given HP treatment. Arterial blood gas analysis was performed, and serum inflammatory mediators, peak airway pressure and lung compliance were detected. Period at ICU stay, duration of mechanical ventilation and 28-day mortality rate were recorded. The ICU stay time, mechanical ventilation time and number of HVHF treatments of HP HVHF group were significantly less than those of HVHF group (P<0.05). There were considerable differences in APACHE II scores between two groups after 24 h and 72 h of treatment (P<0.05). The respiratory index and oxygenation index were significantly different after 72 h (P<0.05). In HP HVHF group, the APACHE II score, respiratory index, oxygenation index, peak airway pressure and lung compliance were considerably improved after 24 h and 72 h (P<0.05). Such values of HVHF group after 72 h of treatment were also improved as compared with those before treatment (P<0.05). The levels of TNF-α, IL-6 and IL-8 in HP HVHF group after 24 h and 72 h were significantly lower as compared to those before treatment (P<0.05). HP plus HVHF reduced the peak concentrations of cytokines affecting lung function, alleviated symptoms and improved prognosis of patients with ARDS.
Keywords
hemoperfusion; high volume hemofiltration; acute respiratory distress syndrome